Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Formoterol

pMDI 12 mcg/dose 1 dose in the morning and 1 dose in the evening

DRUG

Formoterol

DPI 12 mcg/dose 1 dose in the morning and 1 dose in the evening

DRUG

Placebo

Placebo pMDI/DPI 1 dose in the morning and 1 dose in the evening

Trial Locations (1)

16132

"Centro Dipartimentale di Fisiopatologia Respiratoria, University of Genoa", Genova

All Listed Sponsors
collaborator

"Vito Brusasco Centro Dipartimentale di Fisiopatologia Respiratoria, University of Genoa, Italy (Co-ordinating centre)"

UNKNOWN

collaborator

"Giovanni Barisione Unità Operativa di Medicina Preventiva e del Lavoro, Laboratorio di Fisiopatologia Respiratoria, S. Martino Hospital, Genoa, Italy"

UNKNOWN

collaborator

Universita degli Studi di Genova

OTHER

collaborator

Cardarelli Hospital

OTHER

collaborator

"Roberto Dal Negro Unità Operativa di Pneumologia, Hospital of Bussolengo (Verona), Italy"

UNKNOWN

collaborator

University of Modena and Reggio Emilia

OTHER

collaborator

"Carlo Mereu Struttura complessa di Pneumologia, S. Corona Hospital, Pietra Ligure (Savona), Italy"

UNKNOWN

collaborator

University of Pisa

OTHER

collaborator

Fondazione Don Carlo Gnocchi Onlus

OTHER

lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT00742248 - Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter